Phase I/II Clinical Trial of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) in Canada

Condition:   COVID-19 Interventions:   Biological: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector);   Biological: Placebo Sponsors:   CanSino Biologics Inc.;   Beijing Institute of Biotechnology;   Canadian Center for Vaccinology Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials